An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
(201)-510-0950